Abstract
The urofacial, or Ochoa, syndrome is characterised by congenital urinary bladder dysfunction together with an abnormal grimace upon smiling, laughing and crying. It can present as fetal megacystis. Postnatal features include urinary incontinence and incomplete bladder emptying due to simultaneous detrusor muscle and bladder outlet contractions. Vesicoureteric reflux is often present, and the condition can be complicated by urosepsis and end-stage renal disease. The syndrome has long been postulated to have neural basis, and it can be familial when it is inherited in an autosomal recessive manner. Most individuals with urofacial syndrome genetically studied to date carry biallelic, postulated functionally null mutations of HPSE2 or, less commonly, of LRIG2. Little is known about the biology of the respective encoded proteins, heparanase 2 and leucine-rich repeats and immunoglobulin-like domains 2. Nevertheless, the observations that heparanase 2 can bind heparan sulphate proteolgycans and inhibit heparanase 1 enzymatic activity and that LRIG2 can modulate receptor tyrosine kinase growth factor signalling each point to biological roles relevant to tissue differentiation. Moreover, both heparanase 2 and LRIG2 proteins are detected in autonomic nerves growing into fetal bladders. The collective evidence is consistent with the hypothesis that urofacial syndrome genes code for proteins which work in a common pathway to facilitate neural growth into, and/or function within, the bladder. This molecular pathway may also have relevance to our understanding of the pathogenesis of other lower tract diseases, including Hinman–Allen syndrome, or non-neurogenic neurogenic bladder, and of the subset of individuals who have primary vesicoureteric reflux accompanied by bladder dysfunction.
Similar content being viewed by others
References
Morris RK, Malin GL, Khan KS, Kilby MD (2010) Systematic review of the effectiveness of antenatal intervention for the treatment of congenital lower urinary tract obstruction. BJOG 117:382–390
Farrugia MK, Woolf AS (2010) Congenital urinary bladder outlet obstruction. Fetal Maternal Med Rev 21:155–173
Woolf AS, Stuart HM, Newman WG (2013) Genetics of human congenital urinary bladder disease. Pediatr Nephrol. doi:10.1007/s00467-013-2472-1
Wiesel A, Queisser-Luft A, Clementi M, Bianca S, Stoll C, EUROSCAN Study Group (2005) Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet 48:131–144
Ochoa B (2004) Can a congenital dysfunctional bladder be diagnosed from a smile? Pediatr Nephrol 19:6–12
Aydogdu O, Burgu B, Demirel F, Soygur T, Ozcakar ZB, Yalcinkaya F, Tekgul S (2010) Ochoa syndrome: a spectrum of urofacial syndrome. Eur J Pediatr 169:431–435
Daly SB, Urquhart JE, Hilton E, McKenzie EA, Kammerer RA, Lewis M, Kerr B, Stuart H, Donnai D, Long DA, Burgu B, Aydogdu O, Derbent M, Garcia-Minaur S, Reardon W, Gener B, Shalev S, Smith R, Woolf AS, Black GC, Newman WG (2010) Mutations in HPSE2 cause urofacial syndrome. Am J Hum Genet 11:963–969
Stuart HM, Roberts NA, Bergu B, Daly SB, Urquhart JE, Bhaskar S, Dickerson J, Mermerkaya M, Silay MS, Lewis MA, Olondriz BO, Gener B, Beetz C, Varga RE, Gülpınar O, Süer E, Yalçınkaya F, Gücük A, Yue WW, Erdogan F, Berry A, Hanley NA, McKenzie EA, Hilton EN, Woolf AS, Newman WG (2013) LRIG2 mutations cause urofacial syndrome. Am J Hum Genet 92:259–264
Benarroch EE (2010) Neural control of the bladder: recent advances and neurologic implications. Neurology 75:1839–1846
Gilpin SA, Gosling JA (1983) Smooth muscle in the wall of the developing human urinary bladder and urethra. J Anat 137:503–512
Jenkins D, Winyard PJ, Woolf AS (2007) Immunohistochemical analysis of Sonic hedgehog signalling in normal human urinary tract development. J Anat 211:620–629
Weber S, Thiele H, Mir S, Toliat MR, Sozeri B, Reutter H, Draaken M, Ludwig M, Altmüller J, Frommolt P, Stuart HM, Ranjzad P, Hanley NA, Jennings R, Newman WG, Wilcox DT, Thiel U, Schlingmann K-P, Beetz R, Hoyer PF, Konrad M, Schaefer F, Nürnberg P, Woolf AS (2011) Muscarinic acetylcholine receptor M3 mutation causes urinary bladder disease and a prune-belly-like syndrome. Am J Hum Genet 89:668–674
Ganesan I, Thomas T (2011) More than meets the smile: facial muscle expression in children with Ochoa syndrome. Med J Malaysia 66:507–509
Pang J, Zhang S, Yang P, Hawkins-Lee B, Zhong J, Zhang Y, Ochoa B, Agundez JAG, Voelckel MA, Gu W, Xiong W-C, Mei L, She JX, Wang CY (2010) Loss-of-Function mutations in HPSE2 Cause the autosomal recessive urofacial syndrome. Am J Hum Genet 11:957–962
Al Badr W, Al Bader S, Otto E, Hildebrandt F, Ackley T, Peng W, Xu J, Li J, Owens KM, Bloom D, Innis JW (2011) Exome capture and massively parallel sequencing identifies a novel HPSE2 mutation in a Saudi Arabian child with Ochoa (urofacial) syndrome. J Pediatr Urol 7:569–573
Mahmood S, Beetz C, Tahir MM, Imran M, Mumtaz R, Bassmann I, Jahic A, Malik M, Nürnberg G, Hassan SA, Rana S, Nürnberg P, Hübner CA (2012) First HPSE2 missense mutation in urofacial syndrome. Clin Genet 81:88–92
McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J, Page M (2000) Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276:1170–1177
Levy-Adam F, Feld S, Cohen-Kaplan V, Steingaus A, Gross M, Arvatz G, Naroditsy I, Ilan N, Doweck I, Vlodavsky I (2010) Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 285:280–289
Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I (2011) The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 30:253–268
Levy-Adam F, Ilan N, Vlodavsky I (2010) Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 20:153–160
Rodrigues LM, Theodoro TR, Matos LL, Mader AM, Milani C, Pinhal MA (2011) Heparanase isoform expression and extracellular matrix remodeling in intervertebral disc degenerative disease. Clinics (Sao Paulo) 66:903–909
Peretti T, Waisberg J, Mader AM, de Matos LL, da Costa RB, Conceição GM, Lopes AC, Nader HB, Pinhal MA (2008) Heparanase 2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol Hepatol 20:756–765
Wiese CB, Ireland S, Fleming NL, Yu J, Valerius MT, Georgas K, Chiu HS, Brennan J, Armstrong J, Little MH, McMahon AP, Southard-Smith EM (2012) A genome-wide screen to identify transcription factors expressed in pelvic ganglia of the lower urinary tract. Front Neurosci 6:130
Online Mendelian Inheritance in Man (OMIM). Available at: http://www.ncbi.nlm.nih.gov/omim. Accessed 22 May 2013
Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, Hedman H (2004) Characterization and tissue-specific expression of human LRIG2. Gene 332:35–43
Guo D, Holmlund C, Henriksson R, Hedman H (2004) The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84:157–165
Homma S, Shimada T, Hikake T, Yaginuma H (2009) Expression pattern of LRR and Ig domain-containing protein (LRRIG protein) in the early mouse embryo. Gene Expr Patterns 9:1–26
Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y (2004) LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23:3270–3281
Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL 3rd, Sweeney C (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279:47050–47056
Wang Y, Poulin EJ, Coffey RJ (2013) LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 108:1765–1770
Zhang Y, Yeung MN, Liu J, Chau CH, Chan YS, Shum DK (2006) Mapping heparanase expression in the spinal cord of adult rats. J Comp Neurol 494:345–357
Navarro FP, Fares RP, Sanchez PE, Nadam J, Georges B, Moulin C, Morales A, Pequignot JM, Bezin L (2008) Brain heparanase expression is up-regulated during postnatal development and hypoxia-induced neovascularization in adult rats. J Neurochem 105:34–45
Cui H, Shao C, Liu Q, Yu W, Fang J, Yu W, Ali A, Ding K (2011) Heparanase enhances nerve-growth-factor-induced PC12 cell neuritogenesis via the p38 MAPK pathway. Biochem J 440:273–282
Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, Bragge H, Henriksson R, Hedman H (2009) Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 29:242–247
Wang B, Han L, Chen R, Cai M, Han F, Lei T, Guo D (2009) Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther 8:1018–1023
Al Mosawi AJ (2007) Identification of nonneurogenic neurogenic bladder in infants. Urology 70:355–356
Vidal I, Héloury Y, Ravasse P, Lenormand L, Leclair MD (2009) Severe bladder dysfunction revealed prenatally or during infancy. J Pediatr Urol 5:3–7
Silay MS, Tanriverdi O, Karatag T, Ozcelik G, Horasanli K, Miroglu C (2011) Twelve-year experience with Hinman-Allen syndrome at a single center. Urology 78:1397–1401
Yeung CK, Godley ML, Dhillon HK, Duffy PG, Ransley PG (1998) Urodynamic patterns in infants with normal lower urinary tracts or primary vesico-ureteric reflux. Br J Urol 81:461–467
Karami H, Razi A, Mazloomfard MM, Javanmard B (2012) Is there any role for urodynamic study in children with high-grade vesicoureteral reflux? Urology 79:888–891
Hufton AL, Vinayagam A, Suhai S, Baker JC (2006) Genomic analysis of Xenopus organizer function. BMC Dev Biol 6:27
McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151:1–14
Courtney SM, Hay PA, Buck RT, Colville CS, Phillips DJ, Scopes DI, Pollard FC, Page MJ, Bennett JM, Hircock ML, McKenzie EA, Bhaman M, Felix R, Stubberfield CR, Turner PR (2005) Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg Med Chem Lett 15:2295–2299
Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, Nakata H, Tohyama S, Hashimoto H, Kodaira M, Okada Y, Seimiya H, Fusaki N, Hasegawa M, Fukuda K (2010) Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7:11–14
Acknowledgments
The authors acknowledge grant support from: Kidney Research UK, Kidneys for Life and the Wellcome Trust. The work was facilitated by the Manchester Biomedical Research Centre and the Greater Manchester Comprehensive Local Research Network.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Woolf, A.S., Stuart, H.M., Roberts, N.A. et al. Urofacial syndrome: a genetic and congenital disease of aberrant urinary bladder innervation. Pediatr Nephrol 29, 513–518 (2014). https://doi.org/10.1007/s00467-013-2552-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-013-2552-2